Comparison of the Treatment of Refractory Bladder Pain Syndrome With DMSO and DMSO With Botulinum Toxin A
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the efficacy of intravesical botulinum A
toxin and DMSO in women with bladder pain syndrome who have not responded to first-line
treatments. Bladder pain syndrome is suprapubic pain with bladder filling as well as
frequency, urgency, and nocturia in the absence of urinary tract infection or other
pathology. DMSO has been shown to reduce pain in women with bladder pain syndrome as well as
increase bladder absorption of various drugs. Botulinum toxin A has also been shown to
improve pain in women with bladder pain syndrome when injected into the bladder suburothelium
via a cystoscope. The main objective of this study is to assess if DMSO can deliver botulinum
toxin to the suburothelium of the bladder to produce the same effect as direct injection of
Botulinum toxin and a better effect than DMSO alone.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
Society for Urodynamics and Female Urology
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A Dimethyl Sulfoxide incobotulinumtoxinA onabotulinumtoxinA